[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100359104":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":47,"collaborators":49,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":19,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Single study arm","STEMI Patients treated with Magmaris resorbable magnesium scaffold",[12],"Device: Magmaris resorbable magnesium scaffold",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Magmaris resorbable magnesium scaffold","Implantation of Magmaris resorbable magnesium scaffold",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Johan Bennett, Dr.","CONTACT","+3216342465","johan.bennett@uzleuven.be",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Johan Bennett","RECRUITING","Leuven","Brabant","3001","Belgium","BE",{"type":36,"coordinates":37},"Point",[38,39],4.70093,50.87959,{"lat":39,"lon":38},[42,44],{"name":28,"role":23,"phone":43,"phoneExt":43,"email":25},"479293854",{"name":45,"role":46,"phone":19,"phoneExt":19,"email":19},"Keir McCutcheon","SUB_INVESTIGATOR",{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[50,52,54,56,59,61,63,65,67],{"name":51,"class":6},"Centre Hospitalier Universitaire Saint Pierre",{"name":53,"class":6},"Universitair Ziekenhuis Brussel",{"name":55,"class":6},"CHU de Charleroi",{"name":57,"class":58},"Jolimont","UNKNOWN",{"name":60,"class":6},"Ziekenhuis Oost-Limburg",{"name":62,"class":6},"University Hospital St Luc, Brussels",{"name":64,"class":6},"Centre Hospitalier Universitaire UCLouvain Namur",{"name":66,"class":58},"Le centre hospitalier EpiCURA",{"name":68,"class":6},"Centre Hospitalier Régional de la Citadelle","100359104","oct-guided-magmaris-rms-in-stemi-100359104",false,"NCT03955731","OCT Guided Magmaris RMS in STEMI","Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction With the Drug-eluting Resorbable Magnesium Scaffold: the BEST- MAG Multicentre Study. (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold).","BESTMAG","Inclusion Criteria:\n\n1. Patients presenting with a ST-elevation myocardial infarction (STEMI) with symptoms onset \\\u003C24 hours or with ongoing symptoms.\n2. Signed patient informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 or \\> 70 years.\n2. Pregnancy or breastfeeding.\n3. Cardiogenic shock.\n4. Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 (as calculated by MDRD formula for estimated GFR) and not on dialysis. Note: chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance.\n5. Infarct-artery reference diameter \\\u003C 2.7 or \\> 4.0 mm (within the segment of the culprit lesion) by visual estimation, and OCT infarct-artery distal reference mean lumen diameter \\\u003C 2.7 or \\> 3.7 mm\n6. Non-optimal vessel preparation after predilatation: residual stenosis \\>30%.\n7. Culprit lesion length \\> 21 mm.\n8. Culprit lesion located within a previously stented segment (stent thrombosis or in-stent restenosis).\n9. Culprit lesion involving a saphenous vein graft.\n10. Culprit lesion involving a bifurcation with an intended two-stent implantation strategy.\n11. Ostial right coronary artery\n12. Severe calcification or tortuosity of the infarct-related artery.\n13. Absolute contraindication to a 12 months dual antiplatelet therapy.\n14. Life expectancy \\\u003C 3 years.\n15. Patients taking oral anticoagulant therapy","ALL","18 Years","70 Years",{"count":81,"type":82},100,"ESTIMATED","INTERVENTIONAL",[85],"NA","Percutaneous treatment of coronary artery disease depends on the implantation of stents within diseased coronary segments. Compared with conventional bare-metal and drug- eluting stents, which remain permanently within the coronary anatomy, bioresorbable scaffolds (BRS) offer several potential advantages due to its resorbable properties. The resorbable magnesium scaffold Magmaris has demonstrated favourable outcomes in patients with stable coronary artery disease. In particular, in comparison to polymeric bioresorbable scaffolds, no cases of stent thrombosis have been reported in over two years of follow-up suggesting that magnesium-based resorbable scaffolds have low thrombogenicity and might be particularly beneficial for patients presenting with ST- segment myocardial infarction. A recent pilot study in eighteen patients supports this concept, which has led to the development of the proposed prospective multicentre study including intra-coronary imaging with long-term clinical follow-up.",[88],"STEMI","2024-07-02",{"date":91,"type":92},"2024-07-03","ACTUAL",{"date":94,"type":92},"2019-02-15",{"date":96,"type":82},"2025-02-15",{"name":5,"class":6},1]